Maya Guglin1, Hammad Khan. 1. Department of Cardiology, University of South Florida, Tampa, Florida 33618, USA. mguglin@health.usf.edu
Abstract
BACKGROUND: Pulmonary hypertension occurs in 60% to 80% of patients with heart failure and is associated with high morbidity and mortality. METHODS AND RESULTS: Pulmonary artery pressure correlates with increased left ventricular end-diastolic pressure. Therefore, pulmonary hypertension is a common feature of heart failure with preserved as well as reduced systolic function. Pulmonary hypertension is partially reversible with normalization of cardiac filling pressures. Pulmonary vasculature remodeling and vasoconstriction create a second component, which does not reverse immediately, but has been shown to improve with vasoactive drugs and especially with left ventricular assist devices. CONCLUSION: Many drugs used for idiopathic pulmonary arterial hypertension are being considered as treatment options for heart failure-related pulmonary hypertension. This is of particular significance in the heart transplant population. Randomized clinical trials with interventions targeting heart failure patients with elevated pulmonary artery pressure would be justified. Copyright 2010 Elsevier Inc. All rights reserved.
BACKGROUND:Pulmonary hypertension occurs in 60% to 80% of patients with heart failure and is associated with high morbidity and mortality. METHODS AND RESULTS: Pulmonary artery pressure correlates with increased left ventricular end-diastolic pressure. Therefore, pulmonary hypertension is a common feature of heart failure with preserved as well as reduced systolic function. Pulmonary hypertension is partially reversible with normalization of cardiac filling pressures. Pulmonary vasculature remodeling and vasoconstriction create a second component, which does not reverse immediately, but has been shown to improve with vasoactive drugs and especially with left ventricular assist devices. CONCLUSION: Many drugs used for idiopathic pulmonary arterial hypertension are being considered as treatment options for heart failure-related pulmonary hypertension. This is of particular significance in the heart transplant population. Randomized clinical trials with interventions targeting heart failurepatients with elevated pulmonary artery pressure would be justified. Copyright 2010 Elsevier Inc. All rights reserved.
Authors: Jennifer L Philip; Thomas M Murphy; David A Schreier; Sydney Stevens; Diana M Tabima; Margie Albrecht; Andrea L Frump; Timothy A Hacker; Tim Lahm; Naomi C Chesler Journal: Am J Physiol Heart Circ Physiol Date: 2019-02-15 Impact factor: 4.733
Authors: Francesca Bursi; Sheila M McNallan; Margaret M Redfield; Vuyisile T Nkomo; Carolyn S P Lam; Susan A Weston; Ruoxiang Jiang; Véronique L Roger Journal: J Am Coll Cardiol Date: 2012-01-17 Impact factor: 24.094
Authors: Veli-Pekka Harjola; Wilfried Mullens; Marek Banaszewski; Johann Bauersachs; Hans-Peter Brunner-La Rocca; Ovidiu Chioncel; Sean P Collins; Wolfram Doehner; Gerasimos S Filippatos; Andreas J Flammer; Valentin Fuhrmann; Mitja Lainscak; Johan Lassus; Matthieu Legrand; Josep Masip; Christian Mueller; Zoltán Papp; John Parissis; Elke Platz; Alain Rudiger; Frank Ruschitzka; Andreas Schäfer; Petar M Seferovic; Hadi Skouri; Mehmet Birhan Yilmaz; Alexandre Mebazaa Journal: Eur J Heart Fail Date: 2017-05-30 Impact factor: 15.534
Authors: Yazhini Ravi; Karuppaiyah Selvendiran; Shan K Naidu; Sarath Meduru; Lucas A Citro; Balázs Bognár; Mahmood Khan; Tamás Kálai; Kálmán Hideg; Periannan Kuppusamy; Chittoor B Sai-Sudhakar Journal: Hypertension Date: 2013-01-21 Impact factor: 10.190